Christopher S Hourigan1, Laura W Dillon1, Gege Gui1, Brent R Logan2, Mingwei Fei2, Jack Ghannam1, Yuesheng Li1, Abel Licon3, Edwin P Alyea4, Asad Bashey5, H Joachim Deeg6, Steven M Devine7, Hugo F Fernandez8, Sergio Giralt9, Mehdi Hamadani10, Alan Howard7, Richard T Maziarz11, David L Porter12, Bart L Scott6, Erica D Warlick13, Marcelo C Pasquini2, Mitchell E Horwitz14. 1. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. 2. Medical College of Wisconsin, Milwaukee, WI. 3. ArcherDX, Boulder, CO. 4. Dana-Farber Cancer Institute, Boston, MA. 5. Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA. 6. Fred Hutchinson Cancer Research Center, Seattle, WA. 7. National Marrow Donor Program and Center for International Blood and Marrow Transplant Research, Minneapolis, MN. 8. Moffitt Cancer Center and Research Institute, Tampa, FL. 9. Memorial Sloan Kettering Cancer Center, New York, NY. 10. West Virginia University Medicine, Morgantown, WV. 11. Knight Cancer Institute, Oregon Health & Science University, Portland, OR. 12. University of Pennsylvania, Philadelphia, PA. 13. University of Minnesota, Minneapolis, MN. 14. Duke University, Durham, NC.
Abstract
PURPOSE: Patients with acute myeloid leukemia (AML) in remission remain at risk for relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable residual disease (MRD) status before alloHCT has been shown to be prognostic. Whether modulation of the intensity of the alloHCT conditioning regimen in patients with AML who test positive for MRD can prevent relapse and improve survival is unknown. METHODS: Ultra-deep, error-corrected sequencing for 13 commonly mutated genes in AML was performed on preconditioning blood from patients treated in a phase III clinical trial that randomly assigned adult patients with myeloid malignancy in morphologic complete remission to myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC). RESULTS: No mutations were detected in 32% of MAC and 37% of RIC recipients; these groups had similar survival (3-year overall survival [OS], 56% v 63%; P = .96). In patients with a detectable mutation (next-generation sequencing [NGS] positive), relapse (3-year cumulative incidence, 19% v 67%; P < .001) and survival (3-year OS, 61% v 43%; P = .02) was significantly different between the MAC and RIC arms, respectively. In multivariable analysis for NGS-positive patients, adjusting for disease risk and donor group, RIC was significantly associated with increased relapse (hazard ratio [HR], 6.38; 95% CI, 3.37 to 12.10; P < .001), decreased relapse-free survival (HR, 2.94; 95% CI, 1.84 to 4.69; P < .001), and decreased OS (HR, 1.97; 95% CI, 1.17 to 3.30; P = .01) compared with MAC. Models of AML MRD also showed benefit for MAC over RIC for those who tested positive. CONCLUSION: This study provides evidence that MAC rather than RIC in patients with AML with genomic evidence of MRD before alloHCT can result in improved survival.
PURPOSE: Patients with acute myeloid leukemia (AML) in remission remain at risk for relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable residual disease (MRD) status before alloHCT has been shown to be prognostic. Whether modulation of the intensity of the alloHCT conditioning regimen in patients with AML who test positive for MRD can prevent relapse and improve survival is unknown. METHODS: Ultra-deep, error-corrected sequencing for 13 commonly mutated genes in AML was performed on preconditioning blood from patients treated in a phase III clinical trial that randomly assigned adult patients with myeloid malignancy in morphologic complete remission to myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC). RESULTS: No mutations were detected in 32% of MAC and 37% of RIC recipients; these groups had similar survival (3-year overall survival [OS], 56% v 63%; P = .96). In patients with a detectable mutation (next-generation sequencing [NGS] positive), relapse (3-year cumulative incidence, 19% v 67%; P < .001) and survival (3-year OS, 61% v 43%; P = .02) was significantly different between the MAC and RIC arms, respectively. In multivariable analysis for NGS-positive patients, adjusting for disease risk and donor group, RIC was significantly associated with increased relapse (hazard ratio [HR], 6.38; 95% CI, 3.37 to 12.10; P < .001), decreased relapse-free survival (HR, 2.94; 95% CI, 1.84 to 4.69; P < .001), and decreased OS (HR, 1.97; 95% CI, 1.17 to 3.30; P = .01) compared with MAC. Models of AML MRD also showed benefit for MAC over RIC for those who tested positive. CONCLUSION: This study provides evidence that MAC rather than RIC in patients with AML with genomic evidence of MRD before alloHCT can result in improved survival.
Authors: Matthew J Walter; Dong Shen; Li Ding; Jin Shao; Daniel C Koboldt; Ken Chen; David E Larson; Michael D McLellan; David Dooling; Rachel Abbott; Robert Fulton; Vincent Magrini; Heather Schmidt; Joelle Kalicki-Veizer; Michelle O'Laughlin; Xian Fan; Marcus Grillot; Sarah Witowski; Sharon Heath; John L Frater; William Eades; Michael Tomasson; Peter Westervelt; John F DiPersio; Daniel C Link; Elaine R Mardis; Timothy J Ley; Richard K Wilson; Timothy A Graubert Journal: N Engl J Med Date: 2012-03-14 Impact factor: 91.245
Authors: Elli Papaemmanuil; Moritz Gerstung; Hartmut Döhner; Peter J Campbell; Lars Bullinger; Verena I Gaidzik; Peter Paschka; Nicola D Roberts; Nicola E Potter; Michael Heuser; Felicitas Thol; Niccolo Bolli; Gunes Gundem; Peter Van Loo; Inigo Martincorena; Peter Ganly; Laura Mudie; Stuart McLaren; Sarah O'Meara; Keiran Raine; David R Jones; Jon W Teague; Adam P Butler; Mel F Greaves; Arnold Ganser; Konstanze Döhner; Richard F Schlenk Journal: N Engl J Med Date: 2016-06-09 Impact factor: 91.245
Authors: Felicitas Thol; Razif Gabdoulline; Alessandro Liebich; Piroska Klement; Johannes Schiller; Christian Kandziora; Lothar Hambach; Michael Stadler; Christian Koenecke; Madita Flintrop; Mira Pankratz; Martin Wichmann; Blerina Neziri; Konstantin Büttner; Bennet Heida; Sabrina Klesse; Anuhar Chaturvedi; Arnold Kloos; Gudrun Göhring; Brigitte Schlegelberger; Verena I Gaidzik; Lars Bullinger; Walter Fiedler; Albert Heim; Iyas Hamwi; Matthias Eder; Jürgen Krauter; Richard F Schlenk; Peter Paschka; Konstanze Döhner; Hartmut Döhner; Arnold Ganser; Michael Heuser Journal: Blood Date: 2018-09-06 Impact factor: 22.113
Authors: Jay P Patel; Mithat Gönen; Maria E Figueroa; Hugo Fernandez; Zhuoxin Sun; Janis Racevskis; Pieter Van Vlierberghe; Igor Dolgalev; Sabrena Thomas; Olga Aminova; Kety Huberman; Janice Cheng; Agnes Viale; Nicholas D Socci; Adriana Heguy; Athena Cherry; Gail Vance; Rodney R Higgins; Rhett P Ketterling; Robert E Gallagher; Mark Litzow; Marcel R M van den Brink; Hillard M Lazarus; Jacob M Rowe; Selina Luger; Adolfo Ferrando; Elisabeth Paietta; Martin S Tallman; Ari Melnick; Omar Abdel-Wahab; Ross L Levine Journal: N Engl J Med Date: 2012-03-14 Impact factor: 91.245
Authors: Ted A Gooley; Jason W Chien; Steven A Pergam; Sangeeta Hingorani; Mohamed L Sorror; Michael Boeckh; Paul J Martin; Brenda M Sandmaier; Kieren A Marr; Frederick R Appelbaum; Rainer Storb; George B McDonald Journal: N Engl J Med Date: 2010-11-25 Impact factor: 91.245
Authors: David Grimwade; Jelena V Jovanovic; Robert K Hills; Elizabeth A Nugent; Yashma Patel; Rajinder Flora; Daniela Diverio; Katy Jones; Hannah Aslett; Elaine Batson; Kristian Rennie; Roger Angell; Richard E Clark; Ellen Solomon; Francesco Lo-Coco; Keith Wheatley; Alan K Burnett Journal: J Clin Oncol Date: 2009-06-08 Impact factor: 44.544
Authors: Mojca Jongen-Lavrencic; Tim Grob; Diana Hanekamp; François G Kavelaars; Adil Al Hinai; Annelieke Zeilemaker; Claudia A J Erpelinck-Verschueren; Patrycja L Gradowska; Rosa Meijer; Jacqueline Cloos; Bart J Biemond; Carlos Graux; Marinus van Marwijk Kooy; Markus G Manz; Thomas Pabst; Jakob R Passweg; Violaine Havelange; Gert J Ossenkoppele; Mathijs A Sanders; Gerrit J Schuurhuis; Bob Löwenberg; Peter J M Valk Journal: N Engl J Med Date: 2018-03-29 Impact factor: 91.245
Authors: John S Welch; Allegra A Petti; Christopher A Miller; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Jack D Baty; Eric J Duncavage; Bevan Tandon; Yi-Shan Lee; Lukas D Wartman; Geoffrey L Uy; Armin Ghobadi; Michael H Tomasson; Iskra Pusic; Rizwan Romee; Todd A Fehniger; Keith E Stockerl-Goldstein; Ravi Vij; Stephen T Oh; Camille N Abboud; Amanda F Cashen; Mark A Schroeder; Meagan A Jacoby; Sharon E Heath; Kierstin Luber; Megan R Janke; Andrew Hantel; Niloufer Khan; Madina J Sukhanova; Randall W Knoebel; Wendy Stock; Timothy A Graubert; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley Journal: N Engl J Med Date: 2016-11-24 Impact factor: 91.245
Authors: Daisuke Araki; Brent L Wood; Megan Othus; Jerald P Radich; Anna B Halpern; Yi Zhou; Marco Mielcarek; Elihu H Estey; Frederick R Appelbaum; Roland B Walter Journal: J Clin Oncol Date: 2015-12-14 Impact factor: 44.544
Authors: Firas El Chaer; Uma Borate; Rémy Duléry; Shernan G Holtan; Arjun Datt Law; Lori Muffly; Samah Nassereddine; Rory M Shallis; Kate Stringaris; Justin Taylor; Steven M Devine; Mohamad Mohty; Christopher S Hourigan Journal: Blood Adv Date: 2021-03-23
Authors: Nicholas J Short; Hind Rafei; Naval Daver; Hyunsoo Hwang; Jing Ning; Jeffrey L Jorgensen; Tapan M Kadia; Courtney D DiNardo; Sa A Wang; Elias Jabbour; Uday Popat; Betul Oran; Jorge Cortes; Marina Konopleva; Musa Yilmaz; Ghayas C Issa; Hagop Kantarjian; Farhad Ravandi Journal: Blood Adv Date: 2020-12-22
Authors: Michael Heuser; Bennet Heida; Konstantin Büttner; Clara Philine Wienecke; Katrin Teich; Carolin Funke; Maximilian Brandes; Piroska Klement; Alessandro Liebich; Martin Wichmann; Blerina Neziri; Anuhar Chaturvedi; Arnold Kloos; Konstantinos Mintzas; Verena I Gaidzik; Peter Paschka; Lars Bullinger; Walter Fiedler; Albert Heim; Wolfram Puppe; Jürgen Krauter; Konstanze Döhner; Hartmut Döhner; Arnold Ganser; Michael Stadler; Lothar Hambach; Razif Gabdoulline; Felicitas Thol Journal: Blood Adv Date: 2021-05-11
Authors: Jack Y Ghannam; Xin Xu; Irina Maric; Laura Dillon; Yuesheng Li; Matthew M Hsieh; Christopher S Hourigan; Courtney D Fitzhugh Journal: Blood Date: 2020-04-02 Impact factor: 22.113
Authors: Roland B Walter; Yishai Ofran; Agnieszka Wierzbowska; Farhad Ravandi; Christopher S Hourigan; Lok Lam Ngai; Adriano Venditti; Francesco Buccisano; Gert J Ossenkoppele; Gail J Roboz Journal: Leukemia Date: 2021-03-23 Impact factor: 11.528
Authors: Zachariah DeFilipp; Linda J Burns; Samantha M Jaglowski; Aaron L Leppin; Steven Pavletic; Bryce Waldman; Daniel J Weisdorf; William A Wood; Nandita Khera Journal: Biol Blood Marrow Transplant Date: 2020-09-10 Impact factor: 5.742